Q3 2020
10 November 2020
Dr. Andreas Eckert
CEO
1
Global Player Focused on
Niche Markets for Radioisotopes
ISOTOPE PRODUCTS
(industrial components)
Products
Services
Trade
Disposal
67 MM EUR
53%**
MEDICAL*
Radiation Therapy
Radiopharma
Lab Devices
Engineering
60 MM EUR
47%**
HOLDING
(non-operative)
*Since January 1, 2020, Eckert & Ziegler has consolidated its Radiation Therapy and Radiopharma segments under the new name MEDICAL
**figures without Holding segment
127 MM EUR Revenues in Q3-2020
2
Slides only for illustration - the spoken word shall be binding
>800 Employees (Headcounts)
18 Sites Worldwide
Results Q3-2020
(MM EUR)
Revenues 126,9
Net Income | 17,7 |
4%
11%
46%
39%
EUROPE | AMERICA | ASIA | MIDDLE EAST & AFRICA |
3
Slides only for illustration - the spoken word shall be binding
Revenue Growth
01-09/2020 Total Revenues: 126,9 mm EUR
01-09/2019 Total Revenues: 133,2 mm EUR
Lost over last year: -6%
80,0 | |
70,0 | |
EUR | 60,0 |
50,0 | |
MM.In | |
30,0 | |
40,0 | |
20,0 | |
10,0 |
- | Isotope Products | Medical | |||||
Q3-2019 | 78,5 | 54,7 | |||||
Q3-2020 | 66,8 | 60,1 | |||||
-17% YoY due to | Pharma Growth | |
Compensates | ||
Corona & Oil Price | ||
4 | Corona | |
incl. discontinued and continued operations
Slides only for illustration - the spoken word shall be binding
Q3 Revenues by Segment 2019/2020
In MM. EUR | |||
-17% YoY, | |||
Corona & Oil | |||
80,0 | |||
70,0 | |||
60,0 | |||
50,0 | ≈ +30% YoY | ||
40,0
-2,7%
30,0
20,0
10,0
-
Isotope Products | Medical | Medical w/o Pharma | Radiopharma | Holding | |||
Q3-2019 | Q3-2020 | ||||||
5
Isotope Products: Revenue Growth Q3-2020, in mm EUR
90
80
- 10,6
70
60
- 1,1
5078,5
66,8
40
30
20
Revenues Q3-2019 | Organic Growth | Exchange Rate Effects | Revenues Q3-2020 |
6 | Slides only for illustration - the spoken word shall be binding |
Medical: Revenue
Growth Q3-2020, in mm EUR
70
60 | + 0,1 | ||
+ 5,3 | |||
50 | |||
40
30
20
+ 54,7
+ 60,1
10
Revenues Q3-2019 | Organic Growth | Exchange Rate Effects | Revenues Q3-2020 |
7 | Slides only for illustration - the spoken word shall be binding |
Net Income - Distribution and Growth
Q3-2020
8 | Slides only for illustration - the spoken word shall be binding |
Net Income Growth
01-09/2020 Total Net Income: 17,7 mm EUR
01-09/2019 Total Net Income: 18,3 mm EUR
Lost over last year: -3,2%
14,0 | ||||||||
12,0 | ||||||||
10,0 | ||||||||
EUR | 8,0 | |||||||
MM. | 6,0 | |||||||
In | ||||||||
4,0 | ||||||||
2,0 | ||||||||
0,0 | Isotope Products | Medical | ||||||
Q3-2019 | 8,5 | 11,0 | ||||||
Q3-2020 | 4,9 | 13,7 | ||||||
9 | Slides only for illustration - the spoken word shall be binding |
Net Income Growth all Segments in Q3-2020, in mm EUR
20,0 | |||||||||||
18,0 | |||||||||||
- 3,6 | + 0,3 | ||||||||||
16,0 | + 2,7 | ||||||||||
14,0 | |||||||||||
12,0 | |||||||||||
10,0 | |||||||||||
18,3 | 17,7 | ||||||||||
8,0 | |||||||||||
6,0
4,0
2,0
0,0
Net income Q3-2019 | Isotope Products | Medical | Holding | Net income Q3-2020 |
10 | Slides only for illustration - the spoken word shall be binding |
Isotope Products: Net Income
Growth Q3-2020, in mm EUR
9
8
7
6 | -3,2 | ||||||
5 | |||||||
+ 8,5 | |||||||
+ 1,8 | |||||||
4 | |||||||
-1,0 | |||||||
3 | |||||||
+ 4,9
2
1
0
Net income Q3-2019 | Organic Growth | Exchange Rate Effects | Tax/Interest/Minorities | Net income Q3-2020 |
11 | Slides only for illustration - the spoken word shall be binding |
Medical: Net Income Growth
Q3-2020, in mm EUR
18,0 | |||||||
16,0 | |||||||
+ 0,6 | |||||||
14,0 | + 3,0 | -1,1 | |||||
12,0 | |||||||
+ 1,7 | |||||||
10,0 | |||||||
8,0
6,0
4,0
2,0
0,0
+ 14,0
+ 11,0
Net income Q3-2019 | Organic Growth | Pipeline and One-Off | Exchange Rate Effects | Tax/Interest/Minorities | Net income Q3-2020 |
12 | Slides only for illustration - the spoken word shall be binding |
Cashflow and Balance Sheet
Q3-2020
13 | Slides only for illustration - the spoken word shall be binding |
Balance Sheet
as of 30/09/2020, in mm EUR
Cash/Stocks | 76 | Equity | 147 |
Receivables | 30 | Minority Interests | 1 |
Inventory | 33 | IFRS 16 Leasing | 19 |
Intangible Assets | 68 | Accruals/Provisions | 61 |
Fixed Assets | 40 | Other Short Term Payables | 46 |
Others | 35 | Other Long Term Payables | 8 |
Total Assets | 282 | Total Liabilities & Equities | 282 |
- Cash at hand of 75 mm EUR + Financial Assets/ Stocks of 1 mm EUR
- Debt Free
- Equity Ratio 52% (+ 2% over Dec. 2019)
14 | Slides only for illustration - the spoken word shall be binding |
Net Liquidity
Q3-2020, in mm EUR
+10 mm EUR | |||||||
Share Buy-Back | |||||||
80 | 80 | ||||||
70 | 70 | ||||||
60 | 60 | ||||||
EUR | 50 | 50 | |||||
MM.In | 40 | 40 | |||||
30 | 30 | ||||||
20 | 20 | ||||||
10 | 10 | ||||||
0 | 0 | ||||||
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | Q3-2020 |
Zahlungsmittel | 22 | 31 | 37 | 58 | 54 | 79 | 75 | |||
Darlehen | 19 | 16 | 12 | 2 | 0 | 0 | 0 | |||
Nettoliquidität | 3 | 15 | 25 | 56 | 54 | 79 | 75 | |||
Folie nur zur Illustration - es gilt das gesprochene Wort
15
Cashflow
Q3-2020, in mm EUR
EBITDA: 34,8 mm. EUR
100,0 | ||||||
90,0 | -9,3 | |||||
17,0 | ||||||
80,0 | -11,0 | |||||
-0,3 | ||||||
70,0 | ||||||
60,0 | ||||||
78,9 | 74,9 | |||||
50,0 | ||||||
40,0
30,0
Liquidity 31.12.19 CF Operating Activities CF Investing Activities CF Financing Activities Exchange Rate Effects Liquidity 30.09.20
* Only Cash at hand without Stocks | |
16 | Slides only for illustration - the spoken word shall be binding |
Stock and Dividend
in EUR/Stock
Share-split 1:3 effective since 4 August 2020
50 | ||||||
1,7 | ||||||
40 | ||||||
1,5 | ||||||
1,3 | 30 | |||||
1,1 | 1,7 | |||||
20 | ||||||
0,9 | ||||||
1,2 | ||||||
10 | ||||||
0,7 | ||||||
0,8 | ||||||
0,6 | 0,6 | 0,7 | ||||
0,6 | ||||||
0,5 | 0 | |||||
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Dividend in EUR/Share | EUR/Aktie | |||||
17 | Slides only for illustration - the spoken word shall be binding |
Corona Update
Expectations for 2020
Folie nur zur Illustration - es gilt das gesprochene Wort
18
Key Elements of
Guidance 1.0/ 2020 (EBIT)
in mm EUR
19 | Slides only for illustration -the spoken word shall be binding |
Q1-Actuals Confirm
Original Guidance 1.0
Guidance | Reality | How are we doing? |
20 | Slides only for illustration - the spoken word shall be binding |
HY Results Suggest
Net Income of ≥ 21 mm EUR
Elements of Guidance 2.0
Equivalent of
-
Euro/ share pre-split
1 Euro/ share post-split
21 | Slides only for illustration - the spoken word shall be binding |
Key Items Remain on Track
- Corona seems to have hit bottom
- Oil price effects seem to have hit bottom
- No negative effects seen in 2020 for radiopharmaceutical business
- Lutetium:
- commercial production started in March 2020
- High degree of purity/ technology confirmed
- Pharmaceutical manufacturing license expected early 2021
- JV in China with TCL Healthcare on HDR moves ahead:
- Focus is the secondary market of 6.000 to 7.000 clinics
- JV necessary due to protectionist procurement policies
- http://www.tcl-healthcare.com.cn/xwdt/show_4.html
- Set-upof Y-90production lines in Chengdu and Boston progresses according to schedule
- Strategic pipeline
- 6 mm USD competitive NIH-NIAID contract awarded for radiation protection pill
Guidance/ short term
Medium term
Strategic
22 | Slides only for illustration - the spoken word shall be binding |
Expansion Strategy
Gallium-68/ Theranostics
Additional Isotopes (e.g. Lu-177)
EZAG today
Treatment
Diagnosis
Additional indications
23 | Slides only for illustration - the spoken word shall be binding |
Expansion Strategy
Yttrium-90/ Radioembolisation
Geographic Expansion | |
Boston(US) site | |
ROW including | Chengdu(PRC) |
China | |
site | |
EZAG
todayEurope
SIRTEX Europe
Customer Base
24 | Slides only for illustration - the spoken word shall be binding |
Short/ Medium Term Goals for
Radiopharma Ingredients
Building Worldwide Supply Chains / Global Network
Status as of March 2020
Lutetium-177
- Validated technology
- Value chain has been completed
- Five reactors qualified thereof two non-European sites
- First deliveries to customers
Status as of March 2020 Yttrium-90
- New production site in Boston initiated
- Production site in Chengdu Chengdu on schedule
- Numerous alliances in the pipeline
Financial Calendar / IR Contact
10 Nov 2020 Quarterly Report III/2020
17 Nov 2020 German Equity Forum
31 March 2021 Annual Financial Statements 2020
(subject to changes)
ISINDE0005659700
Reuters EUZ.DE
IR Contact
Eckert & Ziegler AG
Karolin Riehle
Investor Relations & PR
Robert-Rössle-Str. 10
D-13125 Berlin
Tel. +49 30 94 10 84-138 Fax +49 30 94 10 84-112 karolin.riehle@ezag.de www.ezag.de
26 | Folie nur zur Illustration - es gilt das gesprochene Wort |
Thank you!
27 | Folie nur zur Illustration - es gilt das gesprochene Wort |
Attachments
- Original document
- Permalink
Disclaimer
Eckert & Ziegler AG published this content on 12 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 November 2020 11:34:06 UTC